FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileCingulate Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CINGW
Cingulate Inc. Stock AnalysisComprehensive stock analysis for Cingulate Inc. (CINGW) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCINGW
CINGW
Cingulate Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CINGW
  1. Home
  2. Stocks
  3. Cingulate Inc.

Cingulate Inc.

🇺🇸CINGW•NASDAQ

Cingulate Inc.

🇺🇸CINGW•NASDAQ
Market cap
$24.31K

Your view on CINGW

Mkt Cap
$24.31K
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Cingulate Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Shane J. Schaffer
Headquarters
1901 West 47th Place, Kansas City, KS, US
Industry
Biotechnology
Sector
Healthcare
CEO
Shane J. Schaffer
Headquarters
1901 West 47th Place, Kansas City, KS, US
Description

Cingulate Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to pioneering therapies for central nervous system and neurobiological conditions.

Its leading investigational medicines are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), both designed to manage attention deficit/hyperactivity disorders (ADHD). Furthermore, the company is progressing CTx-2103 for the treatment of anxiety disorders.

Established in 2012, Cingulate Inc. maintains its main office in Kansas City, Kansas, and also operates a facility in Morristown, New Jersey.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Cingulate Inc.. Starting points for Cingulate Inc.: EPS -$5.37, beta -0.91 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Cingulate Inc.. Trailing twelve-month EPS for Cingulate Inc. stands at -$5.37. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$0.47−$0.40−$2.21−$1.81
Lowest estimate−$0.47−$0.40−$2.21−$1.81
Highest estimate−$0.47−$0.40−$2.21−$1.81
Number of analysts1111
A year ago−$0.961−$0.951−$4.131—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$2.36M$4.63M$2.90M$12.17M
Lowest estimate$2.36M$4.63M$2.90M$12.17M
Highest estimate$2.36M$4.63M$2.90M$12.17M
Number of analysts5355
A year ago$0.00$0.00$0.00—
Growth vs a year ago————

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Cingulate Inc.. Cingulate Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold CINGW19 companies
Compare CINGW with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
APVOAptevo Therapeutics Inc.HealthcareBiotechnology$883,709
BOLTBolt Biotherapeutics, Inc.HealthcareBiotechnology$12.8M
COCPCocrystal Pharma, Inc.HealthcareBiotechnology$18.3M
ERNAErnexa Therapeutics Inc.HealthcareBiotechnology$2.3M
EVGNEvogene Ltd.HealthcareBiotechnology$2.7M
INABIN8bio, Inc.HealthcareBiotechnology$8.2M
KALAKALA BIO, Inc.HealthcareBiotechnology$1.7M
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
AZTRAzitra, Inc.HealthcareAMEX$3.1M
BBIOBridgeBio Pharma, Inc.HealthcareNASDAQ$14.8B
BBIXFBonus BioGroup Ltd.HealthcareOTC$157.7M
BBLGBone Biologics CorporationHealthcareNASDAQ$909,962
BBLGWBone Biologics CorporationHealthcareNASDAQ$1.5M
BBOTBridgeBio Oncology Therapeutics Inc.HealthcareNASDAQ$145.3M
BBTXBambusa Therapeutics Inc.HealthcareNASDAQ$815.1M
BCABBioAtla, Inc.HealthcareNASDAQ$2.9M
BCAXBicara Therapeutics Inc. Common StockHealthcareNASDAQ$560.3M
BCDABioCardia, Inc.HealthcareNASDAQ$11.9M
BCHMFBachem Holding AGHealthcareOTC$4.5B
BCLIBrainstorm Cell Therapeutics Inc.HealthcareOTC$6.8M
Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Cingulate Inc., and how their positions are changing. At a $24,313 market value, institutional positions materially move Cingulate Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Cingulate Inc. executives and directors. Shares of Cingulate Inc. have traded between $0.0093 and $0.04 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Cingulate Inc.. Coverage tracks Cingulate Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Cingulate Inc.

CINGW AnalysisFair
Past
1
Growth
2
Health
5
Profit
1
Value
1